Page last updated: 2024-08-26

sr141716 and Complications of Diabetes Mellitus

sr141716 has been researched along with Complications of Diabetes Mellitus in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bocquier, A; Bouvenot, G; Bouvenot, J; Cortaredona, S; Jardin, M; Nauleau, S; Sauze, L; Sciortino, V; Verger, P1
Saavedra, LE1

Reviews

1 review(s) available for sr141716 and Complications of Diabetes Mellitus

ArticleYear
Endocannabinoid system and cardiometabolic risk.
    Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5

    Topics: Abdominal Fat; Adipokines; Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocannabinoids; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss

2007

Other Studies

1 other study(ies) available for sr141716 and Complications of Diabetes Mellitus

ArticleYear
Feedback and lessons from the prescription of rimonabant, a drug to be used under strict guidelines, in southeastern France, March 2007 through June 2008.
    Revue d'epidemiologie et de sante publique, 2011, Volume: 59, Issue:2

    Topics: Adult; Antidepressive Agents; Body Mass Index; Depressive Disorder; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Prescriptions; Feedback; Female; France; Humans; Insurance, Health, Reimbursement; Logistic Models; Male; Middle Aged; Obesity; Piperidines; Practice Guidelines as Topic; Pyrazoles; Retrospective Studies; Rimonabant

2011